ANXA5 and Venous thrombosis: IgG anti-ANXA5 antibodies were associated with arterial thrombotic events in 170 APS patients and 104 non-APS patients (OR 2.60; 95% CI, 1.44–4.71) and with venous thrombosis events (OR, 2.80; 95% CI, 1.55–5.06); thus, IgG anti-ANXA5 antibodies can be used as predictive biomarkers to identify patients at high risk of thrombosis (28–30).